

# Ninian N Lang

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1649083/publications.pdf>

Version: 2024-02-01

74  
papers

2,245  
citations

279798  
23  
h-index

233421  
45  
g-index

82  
all docs

82  
docs citations

82  
times ranked

3268  
citing authors

#	ARTICLE	IF	CITATIONS
1	Effect of Empagliflozin on Left Ventricular Volumes in Patients With Type 2 Diabetes, or Prediabetes, and Heart Failure With Reduced Ejection Fraction (SUGAR-DM-HF). <i>Circulation</i> , 2021, 143, 516-525.	1.6	237
2	UVA Irradiation of Human Skin Vasodilates Arterial Vasculature and Lowers Blood Pressure Independently of Nitric Oxide Synthase. <i>Journal of Investigative Dermatology</i> , 2014, 134, 1839-1846.	0.7	213
3	Defining cardiovascular toxicities of cancer therapies: an International Cardio-Oncology Society (IC-OS) consensus statement. <i>European Heart Journal</i> , 2022, 43, 280-299.	2.2	213
4	Vascular Complications of Cancer Chemotherapy. <i>Canadian Journal of Cardiology</i> , 2016, 32, 852-862.	1.7	158
5	Ultrasmall Superparamagnetic Particles of Iron Oxide in Patients With Acute Myocardial Infarction. <i>Circulation: Cardiovascular Imaging</i> , 2012, 5, 559-565.	2.6	148
6	Prevalence of Coronary Artery Disease and Coronary Microvascular Dysfunction in Patients With Heart Failure With Preserved Ejection Fraction. <i>JAMA Cardiology</i> , 2021, 6, 1130.	6.1	114
7	In Vivo Mononuclear Cell Tracking Using Superparamagnetic Particles of Iron Oxide. <i>Circulation: Cardiovascular Imaging</i> , 2012, 5, 509-517.	2.6	100
8	Cardiovascular Effects of a Novel SIRT1 Activator, SRT2104, in Otherwise Healthy Cigarette Smokers. <i>Journal of the American Heart Association</i> , 2013, 2, e000042.	3.7	82
9	Recent Advances in Hypertension and Cardiovascular Toxicities With Vascular Endothelial Growth Factor Inhibition. <i>Hypertension</i> , 2017, 70, 220-226.	2.7	76
10	Hypertension and Prohypertensive Antineoplastic Therapies in Cancer Patients. <i>Circulation Research</i> , 2021, 128, 1040-1061.	4.5	59
11	Drug Treatment of Hypertension: Focus on Vascular Health. <i>Drugs</i> , 2016, 76, 1529-1550.	10.9	53
12	Toxicity of cancer therapy: what the cardiologist needs to know about angiogenesis inhibitors. <i>Heart</i> , 2018, 104, 1995-2002.	2.9	51
13	Connexin 43 mediates endothelium-derived hyperpolarizing factor-induced vasodilatation in subcutaneous resistance arteries from healthy pregnant women. <i>American Journal of Physiology - Heart and Circulatory Physiology</i> , 2007, 292, H1026-H1032.	3.2	50
14	Cardiotoxic effects of angiogenesis inhibitors. <i>Clinical Science</i> , 2021, 135, 71-100.	4.3	46
15	A multisystem, cardio-renal investigation of post-COVID-19 illness. <i>Nature Medicine</i> , 2022, 28, 1303-1313.	30.7	39
16	Cardiovascular effects of urocortin 2 and urocortin 3 in patients with chronic heart failure. <i>British Journal of Clinical Pharmacology</i> , 2016, 82, 974-982.	2.4	34
17	Vascular toxicity associated with anti-angiogenic drugs. <i>Clinical Science</i> , 2020, 134, 2503-2520.	4.3	33
18	The Chief Scientist Office Cardiovascular and Pulmonary Imaging in SARS Coronavirus disease-19 (CISCO-19) study. <i>Cardiovascular Research</i> , 2020, 116, 2185-2196.	3.8	31

#	ARTICLE	IF	CITATIONS
19	Urocortins in heart failure. <i>Biochemical Pharmacology</i> , 2010, 80, 289-296.	4.4	27
20	Effects of the small molecule SIRT1 activator, SRT2104 on arterial stiffness in otherwise healthy cigarette smokers and subjects with type 2 diabetes mellitus. <i>Open Heart</i> , 2016, 3, e000402.	2.3	27
21	Effect of PSiâ€697, a Novel Pâ€Selectin Inhibitor, on Plateletâ€Monocyte Aggregate Formation in Humans. <i>Journal of the American Heart Association</i> , 2013, 2, e006007.	3.7	26
22	Role of the Endothelium in the Vascular Effects of the Thrombin Receptor (Protease-Activated) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 622	2.8	25
23	Marked Impairment of Protease-Activated Receptor Type 1-Mediated Vasodilation and Fibrinolysis in Cigarette Smokers. <i>Journal of the American College of Cardiology</i> , 2008, 52, 33-39.	2.8	25
24	Kidney function and cancer risk: An analysis using creatinine and cystatin C in a cohort study. <i>EClinicalMedicine</i> , 2021, 38, 101030.	7.1	24
25	Vascular Effects of Urocortins 2 and 3 in Healthy Volunteers. <i>Journal of the American Heart Association</i> , 2013, 2, e004267.	3.7	21
26	Comprehensive Characterization of the Vascular Effects of Cisplatin-Based Chemotherapy in Patients With Testicularâ€Cancer. <i>JACC: CardioOncology</i> , 2020, 2, 443-455.	4.0	20
27	Clinical Characteristics and Outcomes of Patients With Heart Failure With Reduced Ejection Fraction and Chronic Obstructive Pulmonary Disease: Insights From PARADIGMâ€CHF. <i>Journal of the American Heart Association</i> , 2021, 10, e019238.	3.7	20
28	Role of Asymmetric Methylarginine and Connexin 43â€in the Regulation of Pulmonary Endothelial Function. <i>Pulmonary Circulation</i> , 2013, 3, 675-691.	1.7	19
29	Cardiometabolic effects of a novel SIRT1 activator, SRT2104, in people with type 2 diabetes mellitus. <i>Open Heart</i> , 2017, 4, e000647.	2.3	19
30	The vascular effects of rotigaptide in vivo in man. <i>Biochemical Pharmacology</i> , 2008, 76, 1194-1200.	4.4	18
31	Clonal haematopoiesis of indeterminate potential: intersections between inflammation, vascular disease and heart failure. <i>Clinical Science</i> , 2021, 135, 991-1007.	4.3	18
32	Mechanistic and Clinical Overview Cardiovascular Toxicity of BRAF and MEKâ€Inhibitors. <i>JACC: CardioOncology</i> , 2022, 4, 1-18.	4.0	18
33	Effects of a Novel Nitroxyl Donor in Acute Heartâ€Failure. <i>JACC: Heart Failure</i> , 2021, 9, 146-157.	4.1	17
34	The â€otherâ€™ big complication: how chronic kidney disease impacts on cancer risks and outcomes. <i>Nephrology Dialysis Transplantation</i> , 2023, 38, 1071-1079.	0.7	16
35	Rotigaptide protects the myocardium and arterial vasculature from ischaemia reperfusion injury. <i>British Journal of Clinical Pharmacology</i> , 2016, 81, 1037-1045.	2.4	15
36	The ease of use and reproducibility of the Alereâ€, Heart Check System: a comparison of patient and healthcare professional measurement of BNP. <i>Biomarkers in Medicine</i> , 2014, 8, 791-796.	1.4	14

#	ARTICLE	IF	CITATIONS
37	Haemodynamic effects of the nitroxyl donor cimlanod (<scp>BMS</scp>â€986231) in chronic heart failure: a randomized trial. <i>European Journal of Heart Failure</i> , 2021, 23, 1147-1155.	7.1	13
38	Emerging Thrombotic Effects of Drug Eluting Stents. <i>Arteriosclerosis, Thrombosis, and Vascular Biology</i> , 2007, 27, 261-262.	2.4	12
39	Cardiotoxicity and myocardial hypoperfusion associated with antiâ€vascular endothelial growth factor therapies: prospective cardiac magnetic resonance imaging in patients with cancer. <i>European Journal of Heart Failure</i> , 2020, 22, 1276-1277.	7.1	12
40	Biomarkers of acute rejection following cardiac transplantation. <i>Biomarkers in Medicine</i> , 2014, 8, 815-832.	1.4	10
41	Left ventricular dysfunction with preserved ejection fraction: the most common left ventricular disorder in chronic kidney disease patients. <i>CKJ: Clinical Kidney Journal</i> , 2022, 15, 2186-2199.	2.9	9
42	Vericiguat in worsening heart failure: agonising over, or celebrating, agonism in the VICTORIA trial. <i>Cardiovascular Research</i> , 2020, 116, e152-e155.	3.8	8
43	EMPEROR-REDUCED reigns while EMPERIAL whimpers. <i>European Heart Journal</i> , 2021, 42, 711-714.	2.2	8
44	Personalized medicine and hospitalization for heart failure: if we understand it, we may be successful in treating it. <i>European Journal of Heart Failure</i> , 2019, 21, 699-702.	7.1	7
45	Vascular B1 Kinin Receptors in Patients With Congestive Heart Failure. <i>Journal of Cardiovascular Pharmacology</i> , 2008, 52, 438-444.	1.9	6
46	Vascular PAR-1: Activity and Antagonism. <i>Cardiovascular Therapeutics</i> , 2011, 29, 349-361.	2.5	6
47	Vasomotor and fibrinolytic responses to kinin receptor agonists in the atherosclerotic human lower limb. <i>Heart and Vessels</i> , 2012, 27, 179-185.	1.2	6
48	Adult Congenital Heart Disease and Radiation Exposure. <i>Circulation</i> , 2018, 137, 1346-1348.	1.6	5
49	Acute vascular effects of vascular endothelial growth factor inhibition in the forearm arterial circulation. <i>Journal of Hypertension</i> , 2020, 38, 257-265.	0.5	5
50	Emerging biomarkers for heart failure: an update. <i>Biomarkers in Medicine</i> , 2014, 8, 833-840.	1.4	4
51	Hypertension and Antiangiogenesis. <i>JACC: CardioOncology</i> , 2019, 1, 37-40.	4.0	4
52	Novel oral anticoagulants for the prevention of thromboembolism in patients with atrial fibrillation. <i>Journal of the Royal College of Physicians of Edinburgh, The</i> , 2013, 43, 151-158.	0.6	3
53	Cisplatin related cardiotoxicity â€“ acute and chronic cardiovascular morbidity in a testicular cancer survivor. <i>Scottish Medical Journal</i> , 2020, 65, 24-27.	1.3	3
54	Mechanistic science in cardiovascular-oncology: the way forward to maximise anti-cancer drug effects and minimise cardiovascular toxicity. <i>Clinical Science</i> , 2021, 135, 2661-2663.	4.3	3

#	ARTICLE	IF	CITATIONS
55	Cardiac compression causing fatal acute ST-segment elevation myocardial infarction. QJM - Monthly Journal of the Association of Physicians, 2012, 105, 883-885.	0.5	2
56	Quantitative myocardial inflammation assessed using a novel USPIO-Magnetic Resonance Imaging acquisition and analysis protocol. Journal of Cardiovascular Magnetic Resonance, 2013, 15, O114.	3.3	2
57	Progressive Hypertension and Severe Left Ventricular Outflow Tract Obstruction. Hypertension, 2019, 74, 1216-1225.	2.7	2
58	Pulmonary thromboembolism in hospitalised patients with COVID-19: a retrospective national study of patients managed in critical care and ward environments in Scotland. BMJ Open, 2021, 11, e050281.	1.9	2
59	Current drug therapies for the secondary prevention of MI. The Prescriber, 2008, 19, 14-25.	0.3	1
60	Current drug therapies used in the secondary prevention of MI. The Prescriber, 2010, 21, 22-45.	0.3	1
61	Interventricular lead separation is critical for NT-proBNP reduction after cardiac resynchronization therapy. Biomarkers in Medicine, 2014, 8, 797-806.	1.4	1
62	Chapter 3 Investigation of patients with suspected chronic heart failure. , 2008, , .		1
63	5.1 ENHANCED COMMUNICATION VIA GAP JUNCTIONS PROTECTS THE ENDOTHELIUM FROM ISCHAEMIA-REPERFUSION INJURY IN VIVO IN MAN. Artery Research, 2010, 4, 147.	0.6	0
64	The role of ADMA in the regulation of pulmonary endothelial cell-to-cell communication, endothelial permeability and angiogenesis. Vascular Pharmacology, 2012, 56, 333-334.	2.1	0
65	Cardiology Symposium. Journal of the Royal College of Physicians of Edinburgh, The, 2013, 43, 159-160.	0.6	0
66	Cardiovascular Complications from Cancer Therapy. , 2016, , 185-211.		0
67	Antihypertensive Drugs and Vascular Health. Updates in Hypertension and Cardiovascular Protection, 2019, , 585-605.	0.1	0
68	MULTI-PARAMETRIC CARDIAC MAGNETIC RESONANCE MARKERS OF ANGIOGENESIS INHIBITOR-INDUCED CARDIOTOXICITY. Journal of the American College of Cardiology, 2020, 75, 1672.	2.8	0
69	Cardiovascular Oncologic Emergencies. , 2021, , 269-290.		0
70	Reply. JACC: CardioOncology, 2021, 3, 166.	4.0	0
71	Abstract 44: VEGF Inhibitor-induced Vascular Dysfunction Is Ameliorated By PARP/TRPM2 Inhibition. Hypertension, 2021, 78, .	2.7	0
72	Heart failure resistant to standard medical therapy. , 2014, , 209-226.		0

#	ARTICLE	IF	CITATIONS
73	Vascular Biology of Cancer Chemotherapeutic Drugs. , 2019, , 259-268.		0
74	Abstract P1-13-02: Dynamic changes in high-sensitivity cardiac troponin I in response to anthracycline-based chemotherapy-The Cardiac Care Trial pilot data. , 2020, , .		0